Astellas Pharma Technologies, Inc.

Manufacturer Details

There are currently no manufacturer details available.

Share This Page

Astellas Pharma Technologies, Inc. Drugs

  • Vesicare (Solifenacin Succinate) Tablet, Film Coated [Astellas Pharma Technologies, Inc.]

    Vesicare

    Vesicare (Solifenacin Succinate) Tablet, Film Coated [Astellas Pharma Technologies, Inc.]

    2.1 Dosing Information

    The recommended dose of VESIcare is 5 mg once daily. If the 5 mg dose is well tolerated, the dose may be increased to 10 mg once daily.

    VESIcare should be taken with water and swallowed whole. VESIcare can be administered with or without food.

    2.2 Dose Adjustment in Patients with Renal Impairment

    For patients with severe renal impairment (CLcr <30 mL/min), a daily dose of VESIcare greater than 5 mg is not recommended [see Warnings and Precautions (5.7); Use in Specific Populations (8.6)].

    2.3 Dose Adjustment in Patients with Hepatic Impairment

    For patients with moderate hepatic impairment (Child-Pugh B), a daily dose of VESIcare greater than 5 mg is not recommended. Use of VESIcare in patients with severe hepatic impairment (Child-Pugh C) is not recommended [see Warnings and Precautions (5.6); Use in Specific Populations (8.7)].

    2.4 Dose Adjustment in Patients Taking CYP3A4 Inhibitors

    When administered with potent CYP3A4 inhibitors such as ketoconazole, a daily dose of VESIcare greater than 5 mg is not recommended [see Drug Interactions (7.1)].